IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Kuzmich, Daniel U.S. Appln. No. : 10/739,208 Confirmation No. : 1223 U.S. Filing Date : December 18, 2003 Title of Invention : Glucocorticoid Mimetics, M Compositions and Uses There Attny. Docket No. : 9/272		1625 D. Margaret Seamzn g Them, Pharmaceutical
Mail Stop Amendment ELECTRONICALLY SUBMITTED VIA EFS Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450		
CERTIFICATION STATEMENT, FEE A LETTER FOR INFORMATION		
Sir:		
Transmitted herewith concerning the subject app (Form 1449A/B) ("Statement") under 37 C.F.R. shereinbelow.		
INFORMATION PREVIOUSLY CITED U. S. Application No. ("the identified applicant for an earlier effective filling application. The patents, publications, pending U the Statement were previously cited by the Office Office in the parent application in an information CFR 1.98(a)-(c). 37 CFR 1.98(d)	parent application date under 35 U.S. S. applications, in the parent ap	on") is relied on by the above- S.C. 120 for the instant or other information listed in plication or submitted to the
☑ 1.97(b). This Statement is being file of a national application other than a continued p (d); ii) within three (3) months of the date of entrest in international application; iii) before or iv) before the mailing of a first office action at examination under 37 C.F.R. §1.114.	rosecution applic y of the national the mailing of a	stage as set forth in 37 C.F.R. first office action on the merits
☐ 1.97(c). This Statement is being file \$1.97(b), but before the mailing date of: i) a final allowance under 37 C.F.R. §1.311, or iii) an actic application. This Statement is being accompanie	action under 37 on that otherwise	
A statement as specified in 37 C.F	7.R. §1.97(e) [see	below]; or

		The fee set forth in 37 C.F.R. §1.17(p).			
		$\hfill \Box$ The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. $1.17(p)$ to Deposit Account No. 02-2955.			
1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(e) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. §1.17(p).					
	1.97(e	e).			
	Each item of information contained in the Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the instant filing; or				
	the pe	No item of information contained in the Statement was cited in a communication a foreign patent office in a counterpart foreign application, and, to the knowledge of rson signing this certification after making reasonable inquiry, no item of nation contained in the Statement was known to any individual designated in 37 . §1.56(c) more than three (3) months prior to the instant filing.			
		The fee set forth in 37 C.F.R. §1.17(p).			
		$\label{eq:commissioner} \begin{tabular}{ll} \hline & The Commissioner is hereby authorized to charge payment of the $180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955. \\ \hline \end{tabular}$			
was no	☐ 1.704(d). Each item of information contained in the Statement was first cited in any communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in section 1.56(c) more than thirty (30) days prior to the instant filing.				
The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.					
International Search Report and Non-English Language References					
provid		nglish-language search report or equivalent paper from a foreign patent office is			
A foreign-language search report or equivalent paper from a foreign patent office is provided, and pertinent parts are translated substantively below:					
	X =	document of particular relevance when it is taken alone			
	Y =	document of particular relevance when it is combined with another such document			
	A =	document defining the general state of the art			

O =	non-written disclosure	
P = intervening document		
T =	document cited to understand the theory or principle underlying the invention	
E =	patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date	
D =	cited in the application	
L =	cited for another reason	
&=	publication of member of same patent family	
Translation of other relevant information on foreign search report:		
Forme Dokum "Abbil abstrac Anmel means means registra	search report, "Seite" means page, "Seiten" means pages, "Verbindungen der I" means Compounds of formula, "Beispiele" means examples, and "das ganze nent" means the entire document, "Spalte" means column, "Zeile" means line, dungen" means Figures, "Anspruch" means Claim, "Zusammenfassung" means t/summary, and "Tabelle" means table, and "Tabellen" means tables "in der dung erwachtt" means cited in the application, "Schema" means scheme, "und" and, "Absatz" means paragraph, "abbildung" means figure, "Absendedatum" date of dispatch, "Anmeldetag" means filing date, "Eintragungstag" means ation date, and Bekanntmachung im Patentblatt" means publication date in the I journal.	
been capplication application	references have been provided in the accompanying Statement because they have ited by patent offices outside the United States in the course of prosecution of ations which are counterparts to the above identified application or have been cited been presented as arguments in applications pending before the Office that have t matter related to the above-identified application.	

Respectfully submitted,

/Timothy X. Witkowski/
Timothy X. Witkowski, Reg. No. 40,232
Attorney for Applicant(s)

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: 203-798-4310

Dated: 2009-02-12